Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma
NCT03744247Phase 3Withdrawn
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2019
- Primary completion
- Jan 2021
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Overall Survival at 12 months. Planned start Apr 2019; status: withdrawn.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03744247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03744247.